Key facts
- It has raised $105.4M; the latest was Grant ($1.2M) in Oct 2025.
- Notable investors include Participatiemaatschappij Vlaanderen, Innovation Partnerships, Perceptive Advisors, Wellington Partners, University of Michigan Endowment — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Confo Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Confo Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Confo Therapeutics
Developer of a drug discovery company intended to discover drugs for single-domain antibodies. The company is building a portfolio of programs based on its proprietary technology, which derives specialized camelid single-domain antibodies that stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry with novel agonists for improved therapeutic intervention.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2015
- Employees
- 77
- Website
- confotherapeutics.com/
- Ownership
- Privately Held (backing)
Confo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Confo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Confo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.